ArticleMacromolecular bioscience2026
Development and Characterization of a Structurally Supportive of Hybrid PLGA Decellularized ECM Biomembrane for Ocular Progenitor Cell Anchorage and Epithelial Repair.
Article in Macromolecular bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Degenerative ocular diseases are among the leading causes of visual impairment worldwide and require innovative therapeutic approaches capable of promoting tissue regeneration. In this context, biomaterial-based cell therapies have emerged as promising alternatives, although challenges remain regarding the maintenance of a supportive microenvironment after transplantation. This study developed and characterized a hybrid biomembrane composed of poly(lactic-co-glycolic acid) (PLGA) and decellularized corneal extracellular matrix (dCECM) to provide structural and biochemical support for ocular progenitor cells. PLGA membranes were fabricated and coated with dCECM layers. Their morphological, physicochemical, mechanical, and biocompatibility properties were evaluated. Biocompatibility was assessed using stem cells from the apical papilla (SCAP), periodontal ligament (PDLC), and corneal stroma (CSSC). The capacity of the membranes to preserve ocular progenitor markers (PAX6 and RX) and to exert cytoprotective effects on oxidatively damaged retinal pigment epithelial (RPE) cells was also investigated. Hybrid PLGA-dCECM membranes exhibited suitable thickness, increased hydrophilicity, improved tensile strength, and enhanced cell adhesion without evidence of chemical incompatibility. SCAP and CSSC maintained high expression of ocular progenitor markers, while co-culture with injured RPE cells reduced LDH release and cell death. The PLGA-dCECM biomembrane showed both structural support and bioactive cues, supporting its potential application in ocular regenerative therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.